Register entry
- Registered sites
- 0
- Active NDC listings
- 4
- Live patents
- 81
- Exclusivities
- 2
- Countries
- 0
Catalogue
Drug listings by form and route
44 active NDC listings: 4 human prescription drug. By marketing category: NDA 4.
| Dosage form | NDCs |
|---|---|
| capsule | 3 |
| tablet | 1 |
| Route | NDCs |
|---|---|
| oral | 4 |
| Labeller name on the listing | NDCs |
|---|---|
| deciphera pharmaceuticals, llc | 4 |
Exclusivity
Patents and exclusivities
81| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8188113 | QINLOCKripretinib | substance, product | Jul 2030 |
| RE48731 | QINLOCKripretinib | use | Jun 2032 |
| 9181223 | ROMVIMZAvimseltinib | substance, product | Mar 2034 |
| 8461179 | QINLOCKripretinib | substance, product | May 2034 |
| 12285430 | ROMVIMZAvimseltinib | use | Dec 2039 |
| 12485120 | ROMVIMZAvimseltinib | use | Dec 2039 |
| 12582655 | ROMVIMZAvimseltinib | use | Dec 2039 |
| 11103507 | ROMVIMZAvimseltinib | use | Feb 2040 |
| 11679110 | ROMVIMZAvimseltinib | use | Feb 2040 |
| 10966966 | QINLOCKripretinib | use | Aug 2040 |
| 11266635 | QINLOCKripretinib | use | Aug 2040 |
| 11344536 | QINLOCKripretinib | use | Aug 2040 |
| 11426390 | QINLOCKripretinib | use | Aug 2040 |
| 11433056 | QINLOCKripretinib | use | Aug 2040 |
| 11529336 | QINLOCKripretinib | use | Aug 2040 |
| 11534432 | QINLOCKripretinib | use | Aug 2040 |
| 11576904 | QINLOCKripretinib | use | Aug 2040 |
| 11813251 | QINLOCKripretinib | use | Aug 2040 |
| 12023325 | QINLOCKripretinib | use | Aug 2040 |
| 12023326 | QINLOCKripretinib | use | Aug 2040 |
| 12023327 | QINLOCKripretinib | use | Aug 2040 |
| 12059410 | QINLOCKripretinib | use | Aug 2040 |
| 12059411 | QINLOCKripretinib | use | Aug 2040 |
| 12295944 | QINLOCKripretinib | use | Aug 2040 |
| 12318373 | QINLOCKripretinib | use | Aug 2040 |
| 11185535 | QINLOCKripretinib | product | Dec 2040 |
| 11395818 | QINLOCKripretinib | product | Dec 2040 |
| 11576903 | QINLOCKripretinib | product | Dec 2040 |
| 11612591 | QINLOCKripretinib | product | Dec 2040 |
| 11793795 | QINLOCKripretinib | product | Dec 2040 |
| 11801237 | QINLOCKripretinib | product | Dec 2040 |
| 11844788 | QINLOCKripretinib | product | Dec 2040 |
| 11850240 | QINLOCKripretinib | product | Dec 2040 |
| 11850241 | QINLOCKripretinib | product | Dec 2040 |
| 11896585 | QINLOCKripretinib | product | Dec 2040 |
| 11903933 | QINLOCKripretinib | product | Dec 2040 |
| 11911370 | QINLOCKripretinib | product | Dec 2040 |
| 11918564 | QINLOCKripretinib | product | Dec 2040 |
| 11969415 | QINLOCKripretinib | use | Dec 2040 |
| 12023328 | QINLOCKripretinib | use | Dec 2040 |
| 12064422 | QINLOCKripretinib | use | Dec 2040 |
| 12213967 | QINLOCKripretinib | product | Dec 2040 |
| 12213968 | QINLOCKripretinib | product | Dec 2040 |
| 12226406 | QINLOCKripretinib | product | Dec 2040 |
| 12318374 | QINLOCKripretinib | product | Dec 2040 |
| 12708617 | QINLOCKripretinib | use | Dec 2040 |
| 11969414 | QINLOCKripretinib | use | Feb 2041 |
| 11779572 | QINLOCKripretinib | use | Oct 2042 |
| 12447149 | ROMVIMZAvimseltinib | product | Dec 2044 |
| 12528787 | ROMVIMZAvimseltinib | substance, product | Dec 2044 |
| 12551483 | ROMVIMZAvimseltinib | product | Dec 2044 |
| 12617775 | ROMVIMZAvimseltinib | substance, product | Dec 2044 |
| 12643883 | ROMVIMZAvimseltinib | substance, product | Dec 2044 |
| 12509443 | ROMVIMZAvimseltinib | product | Apr 2045 |
| 12686672 | ROMVIMZAvimseltinib | product | Apr 2045 |
| Product | Exclusivity | Until |
|---|---|---|
| QINLOCKRIPRETINIB | ODE-298 Orphan drug | May 2027 |
| ROMVIMZAVIMSELTINIB | NCE New chemical entity | Feb 2030 |
Catalogue
Marketed products
4| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| QINLOCK | Ripretinib | tablet, oral | 73207-101NDA |
| ROMVIMZA | Vimseltinib | capsule, oral | 73207-302NDA |
| ROMVIMZA | Vimseltinib | capsule, oral | 73207-303NDA |
| ROMVIMZA | Vimseltinib | capsule, oral | 73207-304NDA |
Enquiry
Common questions
- Is Deciphera Pharmaceuticals, LLC FDA approved?
- Deciphera Pharmaceuticals, LLC holds no registered establishment of its own; 4 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Deciphera Pharmaceuticals, LLC make?
- 4 products are listed under Deciphera Pharmaceuticals, LLC in the openFDA NDC Directory, most often as capsule; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.